Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC

NCT06632093 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT06632093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC
Lead sponsor
First Hospital of China Medical University
Phase
Observational
Overall status
Recruiting
Start date
September 16, 2024
Completion date
December 30, 2025
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, hepatic arterial infusion chemotherapy, lenvatinib, pd-1, systemic therapy